UBS Remains a Hold on Renault (0NQF)
UBS analyst David Lesne maintained a Hold rating on Renault (0NQF – Research Report) today and set a price target of €47.00. The company's shares closed yesterday at €44.24.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Lesne covers the Industrials sector, focusing on stocks such as Renault, Valeo, and Forvia. According to TipRanks, Lesne has an average return of 3.8% and a 48.47% success rate on recommended stocks.
Currently, the analyst consensus on Renault is a Moderate Buy with an average price target of €52.82.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
42 minutes ago
- Business Insider
Arlo Technologies management to meet with Roth MKM
Meeting to be held in Boston on June 23 hosted by Roth MKM. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
42 minutes ago
- Business Insider
Alector CFO Marc Grasso to depart, Neil Berkley appointed Interim CFO
Alector (ALEC) announced that its CFO, Marc Grasso, M.D., will conclude his tenure with the company, effective June 20 to pursue other opportunities. Neil Berkley the company's Chief Business Officer, will assume the role of Interim CFO while continuing in his current position. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
an hour ago
- Yahoo
UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times
Johnson & Johnson (NYSE:JNJ) is one of the best stocks for a retirement stock portfolio. On June 12, UBS global equity strategist Andrew Garthwaite's team pointed to Johnson & Johnson as one of the top cyclical picks, excluding financials, whose performance tends to move with the broader economy. A smiling baby with an array of baby care products in the foreground. The stock has gained over 9% in 2025 and currently offers a dividend yield of around 3.4%. Most analysts rate it as a hold, though LSEG data suggests there's still over 9% potential upside from current levels. Last month, Goldman Sachs raised its price target on Johnson & Johnson (NYSE:JNJ) from $172 to $176 and added the stock to its conviction list. The firm made the following statement in its May report: 'JNJ is a stable, defensive grower with the industry's strongest balance sheet allowing for continued high [return on invested capital] investments in the Innovative Medicines segment to augment revenue growth.' The firm highlighted that JNJ 'has a strong pipeline,' with 'meaningful revenue opportunities' in treatments for conditions such as multiple myeloma, lung cancer, and other serious illnesses. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
